Civic Intelligence

Destroy Duchenne

EIN 82-3268952 • 501(c)3 • Norco, CA

Profile

Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.

3182 Vandermolen DrNorco, CA 92860

www.destroyduchenne.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2021

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2021

Net Margin

6th percentile

-193%

Higher net margin than 6% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2021

Top Officer Pay

Score unavailable

No value available

No filing with officer rows is available for this organization yet.

Asset Growth

12th percentile

-79%

Faster asset growth than 12% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Revenue Growth

12th percentile

-66%

Faster revenue growth than 12% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Assets

Down

$11,116

Down $41,494 (-79%) from 2020

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Down

$11,116

Down $41,494 (-79%) from 2020

Revenue

Down

$21,520

Down $42,428 (-66%) from 2020

Expenses

Up

$62,995

Up $35,207 (+127%) from 2020

Net Income

Down

-$41,475

Down $77,635 (-215%) from 2020

Trend Graphs

Balance Sheet Trend

Grouped bars show assets, liabilities, and net assets across loaded filings.

$60K$40K$20K$0Assets 2020: $52,610Net Assets 2020: $52,6102020Assets 2021: $11,116Net Assets 2021: $11,1162021

Highlighted filing

2021

Assets$11,116
Liabilities-
Net Assets$11,116

Operations Trend

Revenue, expenses, and net income by year, with the latest filing highlighted.

$100K$50K$0-$50KRevenue 2020: $63,948Expenses 2020: $27,788Net Income 2020: $36,1602020Revenue 2021: $21,520Expenses 2021: $62,995Net Income 2021: -$41,4752021

Highlighted filing

2021

Revenue$21,520
Expenses$62,995
Net Income-$41,475

Filings

Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2021 to Dec 31, 2021
Signed
Mar 4, 2022
Return Version
2021v4.0
Gross Receipts
$21,520
Mission and Program Overview

Mission

Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.

Program Services

DescriptionGrantsExpenses
WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE.-$32,476
OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE.-$27,550
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
LINDA WHITEPresidentPT$0--
JOSHUA SPIEGELVice PresidePT$0--
DAN LANGTreasurerPT$0--
VICKI SUTHERLANDSecretaryPT$0--
Filing and Contact Details

Filer

Filer Name
Destroy Duchenne
EIN
82-3268952
Phone
9514448147
Address
3182 VANDERMOLEN DR, NORCO, CA 92860

Signing Officer

Name
Dan Lang
Title
Treasurer
Phone
9514448147
Signed
2022-03-04
Discuss with paid preparer
Yes

Preparer

Firm
Sackett Financial Group
Address
915 W IMPERIAL HWY STE 160, BREA, CA 92821
Preparer
Braid Deweese CPA
Phone
7146719330
Supplemental Narrative

Additional Explanations

Form 990-ez, Part I, Line 16

Expenses advertising 31,465 bank fees 20 merchant fees 561 office expense 1,000 website 392 equipment expense 58 insurance 756 licenses fee 115 professional fees 1,078 total 35,445

Form 990-ez, Part I, Line 20

BOOK/ RETURN DIFF -19

Form 990-ez, Part III

Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.

Form 990-ez, Part III, Line 28

With the development and rise of gene editing, crispr-cas9, technologies, humanity has a real opportunity to cure virtually all genetic diseases, such as duchenne muscular dystrophy. Gene editing technology has given us the ability to rewrite our dna and correct faulty dna, like mutations that cause diseases. The applications for gene editing to improve the world are nearly endless and we want to be the champion of advancing gene editing to human trials for people with duchenne. It could be said that the current state of gene editing technology, crispr-cas9, is the tool to cure duchenne that needs to be perfected before it can be applied in humans. More scientific studies need to be done to perfect this tool, crispr-cas9, and that is why we so passionately say we need to: complete the cure.

Form 990-ez, Part III, Line 29

Our founder, elijah stacy who is 19 years old, has taken an entire year to write a 100k word autobiography about his life living with duchenne and some of the life lessons he has learned because of it. This book gives an honest and even vulnerable look into what life is really like living with duchenne muscular dystrophy. By properly launching and publicizing the book/elijah's story, we believe we can solve the awareness problem surrounding duchenne muscular dystrophy. We believe this will lead to more drugs being passed by the fda because of a deeper personal understanding of duchenne and we believe it will allow us to raise more funds to accomplish our mission: complete the curetm for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.

Raw XML Appendix133 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0SACKETT FINANCIAL GROUP
IRS990EZ/BooksInCareOfDetail/PhoneNum07146719330
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0915 W IMPERIAL HIGHWAY 160
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0BREA
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd092821
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt052610
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt011116
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt021520
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-41475
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt052610
IRS990EZ/Form990TotalAssetsGrp/EOYAmt011116
IRS990EZ/GrossReceiptsAmt021520
IRS990EZ/InfoInScheduleOPartIIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt052610
IRS990EZ/NetAssetsOrFundBalancesEOYAmt011116
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt052610
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt011116
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt030.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt113.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt216.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt320.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0LINDA WHITE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1JOSHUA SPIEGEL
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2DAN LANG
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3VICKI SUTHERLAND
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0PRESIDENT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1VICE PRESIDE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2TREASURER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3SECRETARY
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherChangesInNetAssetsAmt0-19
IRS990EZ/OtherExpensesTotalAmt035445
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0DESTROY DUCHENNES MISSION IS TO COMPLETE THE CURE FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE.
IRS990EZ/PrintingPublicationsPostageAmt027550
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt1OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE.
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt032476
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt127550
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TotalExpensesAmt062995
IRS990EZ/TotalProgramServiceExpensesAmt060026
IRS990EZ/TotalRevenueAmt021520
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.DESTROYDUCHENNE.ORG
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt021520
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt063948
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt085468
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct01.00000
IRS990ScheduleA/PublicSupportPY170Pct01.00000
IRS990ScheduleA/PublicSupportTotal170Amt085468
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt021520
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt063948
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt085468
IRS990ScheduleA/TotalSupportAmt085468
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0EXPENSES ADVERTISING 31,465 BANK FEES 20 MERCHANT FEES 561 OFFICE EXPENSE 1,000 WEBSITE 392 EQUIPMENT EXPENSE 58 INSURANCE 756 LICENSES FEE 115 PROFESSIONAL FEES 1,078 TOTAL 35,445
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1BOOK/ RETURN DIFF -19
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2DESTROY DUCHENNES MISSION IS TO COMPLETE THE CURE FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990-EZ, PART I, LINE 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990-EZ, PART I, LINE 20
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2FORM 990-EZ, PART III
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3FORM 990-EZ, PART III, LINE 28
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4FORM 990-EZ, PART III, LINE 29
ReturnHeader/BuildTS02022-09-23 18:48:47Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0DAN LANG
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0TREASURER
ReturnHeader/BusinessOfficerGrp/PhoneNum09514448147
ReturnHeader/BusinessOfficerGrp/SignatureDt02022-03-04
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0DESTROY DUCHENNE
ReturnHeader/Filer/BusinessNameControlTxt0DEST
ReturnHeader/Filer/EIN0823268952
ReturnHeader/Filer/PhoneNum09514448147
ReturnHeader/Filer/USAddress/AddressLine1Txt03182 VANDERMOLEN DR
ReturnHeader/Filer/USAddress/CityNm0NORCO
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CA
ReturnHeader/Filer/USAddress/ZIPCd092860
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0330946321
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0SACKETT FINANCIAL GROUP
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0915 W IMPERIAL HWY STE 160
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0BREA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0CA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd092821
ReturnHeader/PreparerPersonGrp/PhoneNum07146719330
ReturnHeader/PreparerPersonGrp/PreparationDt02022-03-04
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0BRAID DEWEESE CPA
ReturnHeader/ReturnTs02022-03-10T18:13:19-06:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0DAN
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0LANG
ReturnHeader/TaxPeriodBeginDt02021-01-01
ReturnHeader/TaxPeriodEndDt02021-12-31
ReturnHeader/TaxYr02021

Document Assets

No mirrored PDF or thumbnail assets are attached yet.